Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
SAUHY Quote, Financials, Valuation and Earnings
Last price:
$11.68
Seasonality move
:
3.73%
Day range:
$11.50 - $12.11
52-week range:
$10.30 - $15.07
Dividend yield:
0.55%
P/E ratio:
41.13x
P/S ratio:
6.27x
P/B ratio:
9.08x
Volume:
68.6K
Avg. volume:
146.4K
1-year change:
-9.32%
Market cap:
$18.6B
Revenue:
$2.8B
EPS (TTM):
$0.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$2.6M | -$1.09 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.51 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
$11.68 | -- | $18.6B | 41.13x | $0.10 | 0.55% | 6.27x |
|
ACIU
AC Immune SA
|
$3.13 | $9.01 | $314.9M | -- | $0.00 | 0% | 61.04x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.99 | $30.00 | $9.8M | 0.77x | $0.00 | 0% | 36.54x |
|
CRSP
CRISPR Therapeutics AG
|
$55.08 | $81.33 | $5.2B | -- | $0.00 | 0% | 125.63x |
|
ONC
BeOne Medicines Ltd.
|
$312.39 | $400.06 | $34.6B | 601.10x | $0.00 | 0% | 6.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
8.93% | 1.281 | -- | 1.08x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SAUHY
Straumann Holding AG
|
-- | -- | 18.35% | 19.62% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Straumann Holding AG vs. Competitors
-
Which has Higher Returns SAUHY or ACIU?
AC Immune SA has a net margin of -- compared to Straumann Holding AG's net margin of -1688.87%. Straumann Holding AG's return on equity of 19.62% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.5B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About SAUHY or ACIU?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 188.23%. Given that AC Immune SA has higher upside potential than Straumann Holding AG, analysts believe AC Immune SA is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 ACIUAC Immune SA4 0 0 -
Is SAUHY or ACIU More Risky?
Straumann Holding AG has a beta of 1.806, which suggesting that the stock is 80.564% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock SAUHY or ACIU?
Straumann Holding AG has a quarterly dividend of $0.10 per share corresponding to a yield of 0.55%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 23.09% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or ACIU?
Straumann Holding AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Straumann Holding AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Straumann Holding AG's price-to-earnings ratio is 41.13x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 6.27x versus 61.04x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG6.27x 41.13x -- -- ACIUAC Immune SA61.04x -- $1.2M -$19.8M
-
Which has Higher Returns SAUHY or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Straumann Holding AG's net margin of -3178.71%. Straumann Holding AG's return on equity of 19.62% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.5B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About SAUHY or ADXN?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 275.47%. Given that Addex Therapeutics Ltd. has higher upside potential than Straumann Holding AG, analysts believe Addex Therapeutics Ltd. is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is SAUHY or ADXN More Risky?
Straumann Holding AG has a beta of 1.806, which suggesting that the stock is 80.564% more volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock SAUHY or ADXN?
Straumann Holding AG has a quarterly dividend of $0.10 per share corresponding to a yield of 0.55%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 23.09% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or ADXN?
Straumann Holding AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Straumann Holding AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Straumann Holding AG's price-to-earnings ratio is 41.13x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 6.27x versus 36.54x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG6.27x 41.13x -- -- ADXNAddex Therapeutics Ltd.36.54x 0.77x $62K -$2M
-
Which has Higher Returns SAUHY or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Straumann Holding AG's net margin of -11973.12%. Straumann Holding AG's return on equity of 19.62% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.5B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About SAUHY or CRSP?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 47.66%. Given that CRISPR Therapeutics AG has higher upside potential than Straumann Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is SAUHY or CRSP More Risky?
Straumann Holding AG has a beta of 1.806, which suggesting that the stock is 80.564% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock SAUHY or CRSP?
Straumann Holding AG has a quarterly dividend of $0.10 per share corresponding to a yield of 0.55%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 23.09% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or CRSP?
Straumann Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Straumann Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Straumann Holding AG's price-to-earnings ratio is 41.13x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 6.27x versus 125.63x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG6.27x 41.13x -- -- CRSPCRISPR Therapeutics AG125.63x -- $889K -$106.4M
-
Which has Higher Returns SAUHY or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Straumann Holding AG's net margin of 8.84%. Straumann Holding AG's return on equity of 19.62% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital SAUHYStraumann Holding AG-- -- $2.5B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About SAUHY or ONC?
Straumann Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.06%. Given that BeOne Medicines Ltd. has higher upside potential than Straumann Holding AG, analysts believe BeOne Medicines Ltd. is more attractive than Straumann Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SAUHYStraumann Holding AG0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is SAUHY or ONC More Risky?
Straumann Holding AG has a beta of 1.806, which suggesting that the stock is 80.564% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock SAUHY or ONC?
Straumann Holding AG has a quarterly dividend of $0.10 per share corresponding to a yield of 0.55%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Straumann Holding AG pays 23.09% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Straumann Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SAUHY or ONC?
Straumann Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Straumann Holding AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Straumann Holding AG's price-to-earnings ratio is 41.13x while BeOne Medicines Ltd.'s PE ratio is 601.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Straumann Holding AG is 6.27x versus 6.98x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAUHYStraumann Holding AG6.27x 41.13x -- -- ONCBeOne Medicines Ltd.6.98x 601.10x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
